Amnestix, is an early stage biotech company founded in 2006, which focuses on novel therapeutics for improving memory associated with a variety of human diseases.
The company was founded on the discoveries of Dietrich Stephan, PhD., Director of the Neurogenomics Division, his associate, Matthew Huentelman, PhD., at the Translational Genomics Institute in Phoenix, Arizona, and collaborators at the University of Zurich.
Working with Amnestix Chief Executive Officer Karoly Nikolich, PhD, the newly formed company is developing small-molecule drugs for memory-related disorders.
The seed funding for Amnestix was provided by Brain Trust Accelerator Fund, L.P.
The company was successfully acquired by Sygnis, a leading biotechnology company in Europe in June 2008.
BrainScope Company, Inc.
BrainScope Company, Inc is a privately held medical neurotechnology company focused initially on Traumatic Brain Injury. The company is developing a new generation of portable, simple-to-use, non-invasive instruments to aid medical professionals in rapidly and objectively providing clinically meaningful information to aid in the assessment of brain function at the initial point of care. The portability and availability of these tools in development could allow patients suffering from brain dysfunctions to be promptly identified, which could help guide clinicians to appropriate steps after the injury has occurred.
Chase Pharmaceuticals is an early stage pharmaceutical company engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with brain disease.
Neurofluidics is an early stage device company which develops novel, targeted and logical treatment approaches for patients suffering from a variety of neurological disorders.
Satoris is an early stage molecular diagnostics company which focuses on developing blood-based tests for neurodegenerative diseases. The company is committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.